Novartis Wins EU Thumbs Up for MS Treatment
Kesimpta could become the first and only self-administered, targeted B-cell therapy for patients in Europe with relapsing forms of multiple sclerosis.
Kesimpta could become the first and only self-administered, targeted B-cell therapy for patients in Europe with relapsing forms of multiple sclerosis.